CINN‑104
Melanoma (Neoantigen Vaccine)
PreclinicalActive
Key Facts
About Cinnagen
Cinnagen leverages a self‑amplifying mRNA platform to create durable, low‑dose therapeutics for rare diseases and cancer.
View full company profileMelanoma (Neoantigen Vaccine)
Cinnagen leverages a self‑amplifying mRNA platform to create durable, low‑dose therapeutics for rare diseases and cancer.
View full company profile